Corporate Profile
SpyGlass Pharma™ was founded in 2019 by Malik Y. Kahook, MD and Glenn Sussman to redefine the treatment of chronic eye diseases through sustained drug delivery.
Originating from the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine, the SpyGlass Drug Delivery Platform integrates known drugs, procedures, and devices to provide long- term disease control and vision preservation. SpyGlass is powered by a team with deep expertise across every phase of ophthalmic innovation—from discovery to late-stage development and commercialization. With decades of experience running large-scale clinical programs and launching category-defining therapies, our leadership combines scientific rigor with proven launch excellence.
Together, we’re advancing a new era of ophthalmic care built on proven science and enduring innovation.